Preclinical Testing of Therapies for Traumatic Brain Injury.

@article{Dewitt2018PreclinicalTO,
  title={Preclinical Testing of Therapies for Traumatic Brain Injury.},
  author={Douglas S. Dewitt and Bridget E. Hawkins and Clifton Edward Dixon and Patrick M Kochanek and William M Armstead and Cameron R 'Dale' Bass and Helen M. Bramlett and Andr{\'a}s B{\"u}ki and W. Dalton Dietrich and Adam R. Ferguson and Edward D. Hall and Ronald L. Hayes and Col Sidney R Hinds and Michelle C. LaPlaca and Joseph B. Long and David F. Meaney and Stefania Mondello and Linda J. Noble-Haeusslein and Samuel M. Poloyac and Donald S. Prough and Claudia Sue Robertson and Kathryn E. Saatman and Sandy Richard Shultz and Deborah A. Shear and Douglas H. Smith and Alex B. Valadka and Pamela VandeVord and Liying Zhang},
  journal={Journal of neurotrauma},
  year={2018}
}
Despite the large number of promising neuroprotective agents identified in experimental traumatic brain injury (TBI) studies, none has yet shown meaningful improvements in long-term outcome in clinical trials. To develop recommendations and guidelines for preclinical testing of pharmacological or biological therapies for TBI, the Moody Project for… CONTINUE READING